<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8450">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833586</url>
  </required_header>
  <id_info>
    <org_study_id>10136024</org_study_id>
    <nct_id>NCT00833586</nct_id>
  </id_info>
  <brief_title>Terbinafine HCl 250 mg Tablet Under Fasting Conditions</brief_title>
  <official_title>The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the relative bioavailability of the test
      formulation of terbinafine tablets with an already marketed reference formulation Lamisil®
      (Novartis Pharmaceuticals), under fasted conditions in healthy, non-tobacco using male and
      female adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">January 2002</completion_date>
  <primary_completion_date type="Actual">January 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration - Terbinafine in Plasma</measure>
    <time_frame>Blood samples collected over 144 hour period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Terbinafine in Plasma</measure>
    <time_frame>Blood samples collected over 144 hour period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Terbinafine in Plasma</measure>
    <time_frame>Blood samples collected over 144 hour period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Terbinafine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamisil®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine HCl 250mg tablets</intervention_name>
    <description>1 x 250 mg</description>
    <arm_group_label>Terbinafine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamisil® 250 mg Tablets</intervention_name>
    <description>1 x 250 mg</description>
    <arm_group_label>Lamisil®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 years or older inclusive with a body mass index (BMI) of 30 or
             less.

          -  Good health as determined by lack of clinically significant abnormalities in health
             assessments performed at screening.

          -  Signed and dated informed consent form, which meets all criteria of current FDA
             regulations

          -  If female and of child bearing potential subjects must be prepared to abstain from
             sexual intercourse or use a reliable barrier method of contraception (e.g. condom,
             IUD) during the duration of the study. Female subjects who have used oral
             contraceptives within 14 days or injected hormonal contraceptives within 180 days of
             dosing will not be allowed to participate.

        Exclusion Criteria:

          -  If female, pregnant, lactating or likely to become pregnant during the study.

          -  History of allergy or sensitivity to terbinafine, or history of any drug
             hypersensitivity or intolerance which, in the opinion of the Investigator, would
             compromise the safety of the subject or the study.

          -  Significant history or current evidence of chronic evidence of chronic infectious
             disease, system disorder ot organ dysfunction.

          -  Presence of gastrointestinal disease ot history of malabsorption within the last
             year.

          -  History of psychiatric disorders occuring within the last two years that required
             hospitalization or medication.

          -  Presence of a medical condition requiring regular treatment with prescription drugs.

          -  Use of pharmacologic agents known to significantly induce or inhibit
             drug-metabolizing enzymes. within 30 days prior to dosing.

          -  Receipt of any drug as part of a research study within 30 days prior to dosing.

          -  Drug or alcohol addition requiring treatment in the past 12 months.

          -  Donation or significant loss of whole blood (480 ml or more) within 30 days or plasma
             within 14 days prior to dosing.

          -  Positive test results for drug of abuse at screening.

          -  Tobacco user within 90 days of the first study dose.

          -  Unable, or unwilling to tolerate multiple venipunctures.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirley Ann Kennedy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novum Pharmaceutical Research Services</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206-3817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>September 2009</verification_date>
  <lastchanged_date>September 11, 2009</lastchanged_date>
  <firstreceived_date>January 30, 2009</firstreceived_date>
  <firstreceived_results_date>July 6, 2009</firstreceived_results_date>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Terbinafine (Test) First</title>
          <description>Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Lamisil® (Reference) First</title>
          <description>Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout: 14 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Terbinafine (Test) First</title>
          <description>Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Lamisil® (Reference) First</title>
          <description>Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Biracial</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration - Terbinafine in Plasma</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 144 hour period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>Terbinafine HCl 250 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lamisil®</title>
            <description>Lamisil® 250 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax - Maximum Observed Concentration - Terbinafine in Plasma</title>
            <description>Bioequivalence based on Cmax</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="840.2" spread="310.8"/>
                  <measurement group_id="O2" value="873.2" spread="299.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>95.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>85.8</ci_lower_limit>
            <ci_upper_limit>105.4</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Terbinafine in Plasma</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 144 hour period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>Terbinafine HCl 250 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lamisil®</title>
            <description>Lamisil® 250 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Terbinafine in Plasma</title>
            <description>Bioequivalence based on AUC0-inf</description>
            <units>ng*h/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4425" spread="1733"/>
                  <measurement group_id="O2" value="4062" spread="2020"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>98.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>82.7</ci_lower_limit>
            <ci_upper_limit>118.4</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Terbinafine in Plasma</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 144 hour period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>Terbinafine HCl 250 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lamisil®</title>
            <description>Lamisil® 250 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Terbinafine in Plasma</title>
            <description>Bioequivalence based on AUC0-t</description>
            <units>ng*h/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3795" spread="1498"/>
                  <measurement group_id="O2" value="3765" spread="1636"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>102.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.0</ci_lower_limit>
            <ci_upper_limit>110.5</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
